Science Translational Medicine · 2013 · 120 citations · 36 references
MedicineOncologyPharmacologyCell SignalingMolecular OncologyTumor ProgressionCancer Cell SignalingCancer ProgressionGrowth Factor SignalingMalignant NeoplasmsSignal Transduction In CancerTargeted Cancer TherapyFibroblast Growth Factor Receptor Signaling
The fibroblast growth factor (FGF) pathway promotes tumor growth and angiogenesis in many solid tumors. Although there has long been interest in FGF pathway inhibitors, development has been complicated: An effective FGF inhibitor must block the activity of multiple mitogenic FGF ligands but must spare the metabolic hormone FGFs (FGF-19, FGF-21, and FGF-23) to avoid unacceptable toxicity. To achieve these design requirements, we engineered a soluble FGF receptor 1 Fc fusion protein, FP-1039. FP-1039 binds tightly to all of the mitogenic FGF ligands, inhibits FGF-stimulated cell proliferation in vitro, blocks FGF- and vascular endothelial growth factor (VEGF)-induced angiogenesis in vivo, and inhibits in vivo growth of a broad range of tumor types. FP-1039 antitumor response is positively correlated with RNA levels of FGF2, FGF18, FGFR1c, FGFR3c, and ETV4; models with genetic aberrations in the FGF pathway, including FGFR1-amplified lung cancer and FGFR2-mutated endometrial cancer, are particularly sensitive to FP-1039-mediated tumor inhibition. FP-1039 does not appreciably bind the hormonal FGFs, because these ligands require a cell surface co-receptor, klotho or β-klotho, for high-affinity binding and signaling. Serum calcium and phosphate levels, which are regulated by FGF-23, are not altered by administration of FP-1039. By selectively blocking nonhormonal FGFs, FP-1039 treatment confers antitumor efficacy without the toxicities associated with other FGF pathway inhibitors.
36
Patterns of somatic mutation in human cancer genomes
Christopher Greenman, Philip Stephens, Raffaella Smith et al. · Nature · 2007 · 3.1K citations · Full text
Life Sciences, Genetics, Oncology +14
Receptor Specificity of the Fibroblast Growth Factor Family
David M. Ornitz, Jennifer S. Colvin, Donald G. McEwen et al. · Journal of Biological Chemistry · 1996 · 1.9K citations · Full text
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
Kenneth E. White, W. Evans, Jeffery L.H. O'Riordan et al. · Nature Genetics · 2000 · 1.5K citations